Insider Trading Alert - EVDY, MSON And MNK Traded By Insiders - TheStreet

Yesterday, Aug. 26, 2015, 121 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $95.86 to $14,679,317.76.

Highlighted Stocks Traded by Insiders:

Everyday Health (EVDY) - FREE Research Report

McCormick Douglas W., who is Director at Everyday Health, bought 10,000 shares at $8.82 on Aug. 26, 2015. Following this transaction, the Director owned 93,579 shares meaning that the stake was boosted by 11.96% with the 10,000-share transaction.

The shares most recently traded at $9.79, up $0.97, or 9.91% since the insider transaction. Historical insider transactions for Everyday Health go as follows:

  • 12-Week # shares sold: 18,877
  • 24-Week # shares sold: 18,877

The average volume for Everyday Health has been 185,700 shares per day over the past 30 days. Everyday Health has a market cap of $282.6 million and is part of the technology sector and computer software & services industry. Shares are down 39.05% year-to-date as of the close of trading on Wednesday.

Everyday Health, Inc. provides digital health and wellness solutions. The company's portfolio includes Websites, mobile applications, and social media assets that provide consumers and healthcare professionals with access to health and wellness content. The company has a P/E ratio of 9.5. Currently, there are 2 analysts who rate Everyday Health a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EVDY - FREE

TheStreet Quant Ratings

rates Everyday Health as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Everyday Health Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Misonix (MSON) - FREE Research Report

McBrayer Patrick A, who is Director at Misonix, bought 100 shares at $9.68 on Aug. 26, 2015. Following this transaction, the Director owned 100 shares meaning that the stake was boosted by 100% with the 100-share transaction.

The shares most recently traded at $11.40, up $1.72, or 15.13% since the insider transaction. Historical insider transactions for Misonix go as follows:

  • 4-Week # shares bought: 15,000
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 15,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 45,000
  • 24-Week # shares sold: 3,500

The average volume for Misonix has been 11,500 shares per day over the past 30 days. Misonix has a market cap of $72.9 million and is part of the health care sector and health services industry. Shares are down 12.69% year-to-date as of the close of trading on Wednesday.

Misonix, Inc., a surgical device company, designs, develops, manufactures, and markets minimally invasive ultrasonic surgical device products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical applications. The company has a P/E ratio of 14.6. Currently, there are no analysts who rate Misonix a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSON - FREE

TheStreet Quant Ratings

rates Misonix as a

hold

. The company's strengths can be seen in multiple areas, such as its increase in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full

Misonix Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mallinckrodt (MNK) - FREE Research Report

Trudeau Mark, who is President & CEO at Mallinckrodt, bought 1,000 shares at $83.08 on Aug. 26, 2015. Following this transaction, the President & CEO owned 166,176 shares meaning that the stake was boosted by 0.61% with the 1,000-share transaction.

The shares most recently traded at $88.58, up $5.50, or 6.21% since the insider transaction. Historical insider transactions for Mallinckrodt go as follows:

  • 4-Week # shares bought: 4,324
  • 4-Week # shares sold: 668
  • 12-Week # shares bought: 5,624
  • 12-Week # shares sold: 668
  • 24-Week # shares bought: 6,624
  • 24-Week # shares sold: 668

The average volume for Mallinckrodt has been 1.6 million shares per day over the past 30 days. Mallinckrodt has a market cap of $9.2 billion and is part of the health care sector and drugs industry. Shares are down 13.34% year-to-date as of the close of trading on Wednesday.

Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. Currently, there are 8 analysts who rate Mallinckrodt a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNK - FREE

TheStreet Quant Ratings

rates Mallinckrodt as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

Mallinckrodt Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.